Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lynch

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Cancer Chemotherapy and Pharmacology|November 1, 2016
Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myelomaChaitali Passey, Raymond Darbenzio, Ying-Ming Jou, et al.
Clinical Chemistry|July 26, 2011
Quality error rates in point-of-care testingMaurice J O'Kane, Paul McManus, Noel McGowan, et al.
Annals of Clinical Biochemistry|February 23, 2011
Clinical outcome indicators, disease prevalence and test request variability in primary careMaurice J O'Kane, Lee Casey, P L Mark Lynch, et al.
The Science of the Total Environment|August 16, 2021
Development of a low-temperature extrusion process for production of GRAS bioactive-polymer loaded compounds for targeting antimicrobial-resistant (AMR) bacteriaKevin Masterson, Elaine Meade, Mary Garvey, et al.
BJU International|May 8, 2014
Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasiblePhilip Brousil, Muddassar Hussain, Mark Lynch, et al.
Molecular Cancer Therapeutics|October 15, 2008
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingScott M Wilhelm, Lila Adnane, Philippa Newell, et al.
Postgraduate Medical Journal|October 23, 2015
Clinical and diagnostic findings in patients with elevated cerebrospinal bilirubinMark O McCarron, Mark Lynch, Peter McCarron, et al.
Cancer Research|December 21, 2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Li Liu, Yichen Cao, Charles Chen, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancerScott Wilhelm, Christopher Carter, Mark Lynch, et al.
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|November 1, 2016
Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myelomaChaitali Passey, Raymond Darbenzio, Ying-Ming Jou, et al.
Clinical Chemistry|July 26, 2011
Quality error rates in point-of-care testingMaurice J O'Kane, Paul McManus, Noel McGowan, et al.
Annals of Clinical Biochemistry|February 23, 2011
Clinical outcome indicators, disease prevalence and test request variability in primary careMaurice J O'Kane, Lee Casey, P L Mark Lynch, et al.
The Science of the Total Environment|August 16, 2021
Development of a low-temperature extrusion process for production of GRAS bioactive-polymer loaded compounds for targeting antimicrobial-resistant (AMR) bacteriaKevin Masterson, Elaine Meade, Mary Garvey, et al.
BJU International|May 8, 2014
Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasiblePhilip Brousil, Muddassar Hussain, Mark Lynch, et al.
Molecular Cancer Therapeutics|October 15, 2008
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingScott M Wilhelm, Lila Adnane, Philippa Newell, et al.
Postgraduate Medical Journal|October 23, 2015
Clinical and diagnostic findings in patients with elevated cerebrospinal bilirubinMark O McCarron, Mark Lynch, Peter McCarron, et al.
Cancer Research|December 21, 2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Li Liu, Yichen Cao, Charles Chen, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancerScott Wilhelm, Christopher Carter, Mark Lynch, et al.
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Pageof 6